

# ROBIN OligoMET Center

## Monthly Research Update: September 2024

### Publications

SEPTEMBER AT A GLANCE TOTALS	
Publications	8
Grants and contracts	
New awards	0
Submitted	4
Oral Presentations	2
Abstracts	0
Clinical trials	
TERPS	2
Awards/Honors	0

Please submit all monthly updates to Jadyne Stewart at [jadynstewart@som.umaryland.edu](mailto:jadynstewart@som.umaryland.edu) by second Wednesday of each month.

- Boufaied N, Chetta P, Hallal T, Cacciatore S, Lalli D, Luthold C, Homsy K, Imada EL, Syamala S, Photopoulos C, Di Matteo A, de Polo A, Storaci AM, Huang Y, Giunchi F, Sheridan PA, Michelotti G, Nguyen QD, Zhao X, Liu Y, Davicioni E, Spratt DE, Sabbioneda S, Maga G, Mucci LA, Ghigna C, **Marchionni L**, Butler LM, Ellis L, Bordeleau F, Loda M, Vaira V, Labbé DP, Zadra G. **Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer.** *Cancer Res.* 2024 Jun 4;84(11):1834-1855. doi: 10.1158/0008-5472.CAN-23-0519. PMID: 38831751; PMCID: PMC11148549.
- Calderon-Aparicio A, He J, **Simone NL.** **S6K1 Controls DNA Damage Signaling Modulated by the MRN Complex to Induce Radioresistance in Lung Cancer.** *Int J Mol Sci.* 2024 Sep 28;25(19):10461. doi: 10.3390/ijms251910461. PMID: 39408794; PMCID: PMC11477310.
- Cappelli L, Uppendahl A, Gardner C, Khan M, Kayne A, Vemula S, Poiset SJ, Zhan T, Judy KD, Andrews DW, **Simone NL**, Alnahhas I, Shi W. **Baseline single institutional retrospective review of body mass index (BMI) as a prognostic indicator in patients with newly diagnosed glioblastoma (GBM).** *J Clin Neurosci.* 2024 Sep;127:110754. doi: 10.1016/j.jocn.2024.07.015. Epub 2024 Jul 27. PMID: 39068727.
- Cherng HR, Sun K, **Bentzen SM, Mishra MV.** **An Exploratory Analysis of the Conditional Neurocognitive Function Failure Risk in Patients Receiving Whole Brain Radiotherapy for Brain Metastases on NRG Oncology CC001: Conditional Neurocognitive Toxicity Risk.** *Int J Radiat Oncol Biol Phys.* 2024 Sep 25:S0360-3016(24)03400-X. doi: 10.1016/j.ijrobp.2024.09.029. Epub ahead of print. PMID: 39332644.
- Nooruzzaman M, Johnson KEE, Rani R, Finkelsztejn EJ, Caserta LC, Kodiyanplakkal RP, Wang W, Hsu J, Salpietro MT, Banakis S, Albert J, Westblade LF, Zanettini C, **Marchionni L**, Soave R, Ghedin E, Diel DG, Salvatore M. **Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.** *Nat Commun.* 2024 Sep 18;15(1):7999. doi: 10.1038/s41467-024-51924-3. PMID: 39294134; PMCID: PMC11411086.
- Omar M**, Harrell JC, Tamimi R, Marchionni L, Erdogan C, Nakshatri H, Ince TA. **A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer.** *Breast Cancer Res.* 2024 Sep 13;26(1):132. doi: 10.1186/s13058-024-01876-9. PMID: 39272208; PMCID: PMC11395215.
- Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, **Tran PT**, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. **Erratum.** *Int J Radiat Oncol Biol Phys.* 2024 Sep 23:S03603016(24)03323-6. Online ahead of print.

## ROBIN OligoMET Center Monthly Research Update: September 2024

### Publications

8. Wisdom AJ, Yeap BY, Michalski JM, Horick NK, Zietman AL, Christodouleas JP, Kamran SC, Parikh RR, Vapiwala N, Mihalcik S, Miyamoto DT, Zeng J, Gay HA, Pisansky TM, **Mishra MV**, Spratt DE, Mendenhall NP, Soffen EM, Bekelman JE, Efstathiou JA. [Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer](#). *Int J Radiat Oncol Biol Phys*. 2024 Sep 30;30:S0360-3016(24)03444-8. doi: 10.1016/j.ijrobp.2024.09.043. Epub ahead of print. PMID: 39357788.

### Grants and Contracts

#### Funded:

- None reported

#### Submitted:

- France Carrier, PhD, and **Erika Davies, PhD, MPls**. Subaward with CMTx Biotech Inc. on NIH STTR[R41/R42] for "A novel host-directed medical countermeasure for the treatment of radiation-induced lung injury" (\$358,428).
- **Lei Ren, PhD, MPI**. Subaward with SUNY–Upstate Medical Center (lead) on NIH/NCI R01 PAR-23-034 for "Enhancing clinical decision-making with generative machine learning by integrating large-scale multimodal healthcare data" (\$559,800).
- **Phuoc Tran, MD, PhD, PI**. Subaward with Rutgers University (Deek) to the American Cancer Society for "ARP inhibition with SABR for high-risk mutation castration-sensitive prostate cancer oligometastatic disease" (\$315,332).
- **Phuoc Tran, MD, PhD, PI**. Subaward with Rutgers University (Deek), on NIH R01 for "Ascertaining multilevel drivers of head and neck cancer disparities (AMEND)" (\$777,500).

### Oral Presentations

- **Phuoc. T.**, Imaging in 20/20: Imaging for Cure - Session 3: Theranostics in precision medicine (September 16, 2024 – Jackson Hole, WY). "The Promise of Theranostics for Oligometastatic Prostate Cancer: Going Beneath the Surface with Molecular Imaging and Radiotherapy".
- **Phuoc. T.**, ASTRO National Meeting, Presidential Symposium - New Innovations in Genitourinary Cancers (September 29, 2024 – Washington DC). "The Space-Time Continuum in Metastatic Castration-Sensitive Prostate Cancer: The Final Frontier?".

### Abstracts

- None reported

### Clinical Trial Enrollment

- 2 patient was enrolled (26/122 total) on the **TERPS trial**.

### Awards/Honors

- None reported

*Please note that these examples are representative of productivity from the ROBIN OligoMET Center members and are not exclusively attributable to the U54 grant.*